Inventor · disambiguated record
Brian Hoel
Also filed as: HOEL BRIAN · HOEL BRIAN D
6 granted patents·5 pending applications·609 citations·filing 1999–2022
80Inventor score
Files withMUSC FOUND FOR RES DEV4PENN STATE RES FOUND2CHARLESTONPHARMA LLC1NORRIS JAMES S1SUTKOWSKI NATALIE1
Top patents by PatentIndex Score
11 records- 0195US6271359B1Tissue-specific and pathogen-specific toxic agents and ribozymesMUSC FOUND FOR RES DEV·Filed 1999·Granted Aug 7, 2001·602 cites·8 claims
- 0276US9260517B2Human monoclonal antibodies to human nucleolinSUTKOWSKI NATALIE·Filed 2010·Granted Feb 16, 2016·5 cites·32 claims
- 0369US7575918B2Tissue-specific and pathogen-specific ribozymesPENN STATE RES FOUND·Filed 2004·Granted Aug 18, 2009·2 cites·10 claims
- 0463US2023190930A1Anti-nucleolin antibodiesMUSC FOUND FOR RES DEV·Filed 2022·Application pending·0 cites
- 0559US2006223774A1Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereofUNIV SOUTH CAROLINA·Filed 2006·Application pending·0 cites
- 0654US2019382478A1Nucleolin AntibodiesMUSC FOUND FOR RES DEV·Filed 2019·Application pending·0 cites
- 0751US7732197B2Tissue-specific and target RNA-specific ribozymesPENN STATE RES FOUND·Filed 2002·Granted Jun 8, 2010·0 cites·15 claims
- 0850US11357849B2Anti-nucleolin antibodiesCHARLESTONPHARMA LLC·Filed 2017·Granted Jun 14, 2022·0 cites·12 claims
- 0949US10385128B2Nucleolin antibodiesMUSC FOUND FOR RES DEV·Filed 2015·Granted Aug 20, 2019·0 cites·12 claims
- 1047US2004220123A1Tissue-specific and pathogens-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereofNORRIS JAMES S·Filed 2001·Application pending·0 cites
- 1144US2005118719A1Nucleic acid delivery and expressionFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Brian Hoel files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →